China Finance App News, Xide Pharmaceutical (301130.SZ) announced that the company has recently received the issuance of the domestic production pharmaceutical holding license holder for rivastigmine tartrate oral solution from the National Medical Products Administration, with a change in the subject matter application "Acceptance Letter", which has been decided to be accepted by the National Medical Products Administration. The announcement indicates that rivastigmine tartrate oral solution is used to treat symptoms of mild to moderate Alzheimer's dementia.